We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pharvaris NV | NASDAQ:PHVS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.93 | -3.95% | 22.60 | 9.31 | 23.77 | 23.90 | 22.475 | 23.77 | 55,488 | 22:34:21 |
From May 2022 to May 2024
By Denny Jacob
Pharvaris NV shares soared 79%, to $4.50, in early trading after the company said data on PHVS416 demonstrated statistically significant results for treatment of hereditary angioedema, a hereditary condition that causes recurrent swelling.
Top-line data from the Phase 2 study of PHVS416 for the prophylactic treatment of hereditary angioedema is expected in the second half of 2023, said Chief Executive Berndt Modig. Data from the proof-of-concept study is expected to inform the design of expected Phase 3 utilizing PHVS719, an investigational treatment currently in Phase 1 clinical development for hereditary angioedema.
The clinical-stage biopharmaceutical company also said it is continuing to work with the U.S. Food and Drug Administration to resolve holds on clinical trials for PHA121, which the company describes as a competitive antagonist of the bradykinin B2 receptor.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 08, 2022 10:20 ET (15:20 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Pharvaris NV Chart |
1 Month Pharvaris NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
